Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients

Journal of Clinical Oncology

Volumn 18, Issue 12, 2000, Pages 2476-2483

  Cagnoni, Pablo J ^a   Walsh, Thomas J ^a   Prendergast, Mary M ^a   Bodensteiner, David ^a   Hiemenz, Sharon ^a   Greenberg, Richard N ^a   Arndt, Carola A S ^a   Schuster, Mindy ^a   Seibel, Nita ^a   Yeldandi, Vijay ^a   Tong, Kuo B ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG FORMULATION; FEBRILE NEUTROPENIA; FEMALE; HOSPITAL COST; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0034045794     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.12.2476     Document Type: Article

References (9)

1. Walsh TJ, Finberg RW, Arndt C, et al: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 340:764-771, 1999
2. Cagnoni PJ, Grethlein S, Korones DN, et al: Improved safety and efficacy of AmBisome (liposomal amphotericin B) compared with amphotericin B in the empirical treatment of febrile neutropenic patients undergoing bone marrow transplantation. Blood 90:420a, 1997 (abstr)
3. Boogaerts MA, Tomans G, Maes E, et al: Cost-effectiveness analysis of AmBisome (AMB) versus amphotericin B (AMPHOB) in the empiric treatment of febrile neutropenia in adults and children. Blood 88:501a, 1996 (abstr)
4. Bates DW, Yu DT, Chertow DL, et al: Resource utilization and amphotericin B associated nephrotoxicity. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 24-27, 1998 (abstr O-11)
5. Wingard JR, Kubilis P, Lee L, et al: Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 29:1402-1407, 1999
6. Gubbins PO: University Health System Consortium Drug Monograph: Liposomal Amphotericin B. Oakbrook, IL, UHC Services Corporation, November 1996
7. Verweij PE, Bos JJ, Severens JL, et al: Cost-effectiveness of liposomal amphotericin B for the treatment of invasive fungal infections in neutropenic patients. Presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 24-28, 1998 (abstr O-14)
8. Lee JT, Sanchez LA: Interpretation of "cost-effective" and soundness of economic evaluations in the pharmacy literature. Am J Hosp Pharm 48:2622-2627, 1991
9. Stewart DJ, Dahrouge S, Coyle D, et al: Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy. J Clin Oncol 17:344-351, 1999